This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Edwards, W. D. Articles by Edwards, J. E. Search for Related Content PubMed PubMed Citation Articles by Edwards, W. D. Articles by Edwards, J. E.

Circulation, Vol 56, 884-888, Copyright © 1977 by American Heart Association

ARTICLES

Clinical primary pulmonary hypertension: three pathologic types

WD Edwards and JE Edwards

Clinically, there is a group of patients with elevated pulmonary arterial pressure in whom the underlying cause is not apparent. The pulmonary arterial wedge pressure is not elevated. For such cases, the designation of primary pulmonary hypertension may be made clinically. From the clinical categorization of primary pulmonary hypertension, three distinct pathologic entities emerge, namely 1) plexogenic pulmonary arteriopathy, 2) recurrent pulmonary thromboembolism, and 3) pulmonary veno-occlusive disease. The plexogenic type is characterized initially by pulmonary arterial vasoconstriction with medial hypertrophy. Secondary proliferative intimal lesions, including the plexiform lesion, develop. Recurrent pulmonary thromboembolism is characterized by the presence of arterial thrombi of varying ages involving the microscopic-sized pulmonary arteries. Thrombi may be embolic in nature or may develop in situ. Pulmonary veno-occlusive disease is characterized by obstructive lesions of pulmonary veins and venules. The clinical presentation of the three pathologic types may be so similar that definitive diagnosis depends upon histologic examination of the lung from tissue obtained either by biopsy or at necropsy.

This article has been cited by other articles:

				S. Mizuno, M. Kadowaki, Y. Demura, S. Ameshima, I. Miyamori, and T. Ishizaki p42/44 Mitogen-Activated Protein Kinase Regulated by p53 and Nitric Oxide in Human Pulmonary Arterial Smooth Muscle Cells Am. J. Respir. Cell Mol. Biol., August 1, 2004; 31(2): 184 - 192. [Abstract] [Full Text] [PDF]

				A. Widlitz and R.J. Barst Pulmonary arterial hypertension in children Eur. Respir. J., January 1, 2003; 21(1): 155 - 176. [Abstract] [Full Text] [PDF]

				E. P. Chen, D. M. Craig, H. B. Bittner, R. D. Davis, and P. Van Trigt Pharmacological Strategies for Improving Diastolic Dysfunction in the Setting of Chronic Pulmonary Hypertension Circulation, April 28, 1998; 97(16): 1606 - 1612. [Abstract] [Full Text] [PDF]

				E. P. Chen, H. B. Bittner, F. Tull, D. Craig, R. D. Davis, and P. Van Trigt NITRIC OXIDE IMPROVES PULMONARY VASCULAR IMPEDANCE, TRANSPULMONARY EFFICIENCY, AND LEFT VENTRICULAR FILLING IN CHRONIC PULMONARY HYPERTENSION J. Thorac. Cardiovasc. Surg., May 1, 1997; 113(5): 849 - 857. [Abstract] [Full Text]

				E. P. Chen, H. B. Bittner, D. M. Craig, R. D. Davis Jr, and P. Van Trigt III Pulmonary Hemodynamics and Blood Flow Characteristics in Chronic Pulmonary Hypertension Ann. Thorac. Surg., March 1, 1997; 63(3): 806 - 813. [Abstract] [Full Text]

				C. A. Nienaber, R. P. Spielmann, R. Montz, W. Bleifeld, and D. G. Mathey Development of Pulmonary Aneurysm in Primary Pulmonary Hypertension: A Case Report Angiology, April 1, 1986; 37(4): 319 - 324. [Abstract] [PDF]